Healio6d
Adding anifrolumab superior to standard therapy alone, maintains remission in lupus
Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity ...
pharmaphorum5d
AZ fleshes out positive trial of revitalised lupus drug anifrolumab
After being all-but written off a year ago, AstraZeneca’s anifrolumab has been reborn with new data that suggest it could help to end a drought in treatments for autoimmune disease systemic ...
pharmaphorum5d
AZ's lupus drug Saphnelo cleared in EU, challenging GSK's Benlysta
Saphnelo (anifrolumab) is the first biologic drug for SLE to be approved in Europe that is not restricted to patients with a high degree of disease activity, according to AZ, which also notes it ...
Frontiers6d
The role of monocytes and macrophages in idiopathic inflammatory myopathies: insights into pathogenesis and potential targets
In subtypes such as dermatomyositis, immune-mediated necrotizing myopathy ... mesenchymal stem cell-derived exosomes (MSC-Exos), JAK inhibitors, anifrolumab, and dazukibart. TO belonged to the Social ...